Third-generation antipsychotics (TGAs), exemplified by aripiprazole, provide a cleaner pharmacological profile and reduced side effect liabilities compared with older drugs such as haloperidol and ...

Meyer: Well, it may not be necessary to have an effective antipsychotic which binds to the D2 receptor. And I think we've improved in tolerability with other compounds, which are antipsychotics in ...

Neumora initiates Phase 1 study for NMRA-861, a potential treatment for schizophrenia with promising pharmacological profile. Quiver AI Summary Neumora Therapeutics, Inc. has announced the ...

Scientists at the UNC School of Medicine and UC San Francisco (UCSF) have solved the first high-resolution crystal structure of the dopamine 2 receptor (DRD2) bound to the antipsychotic drug ...

Primary Source American Psychiatric Association Source Reference: Hopkins S, et al "The safety profile of the TAAR1 agonist, SEP-363856, is distinct from atypical antipsychotics" APA 2021.

Unlike dopamine receptor-targeting schizophrenia therapies, the current standard of care, Cobenfy, is the first FDA-approved antipsychotic targeted at cholinergic receptors.